BACKGROUND: We aimed to diagnose possible acute kidney injury (AKI) with new early biochemical markers in patients who were admitted to the emergency department frequently with mild and moderate brain trauma, and to prevent possible complications, shorten the duration of treatment and hospital stay. With this purpose, we decided to reach our scientific target using the experi-mental rat model. METHODS: Wistar albino rats were included our experiment. Fifteen rats were randomly separated into three groups: Sham control (n=1: Underwent craniotomy alone), control (n=7: Without craniotomy), and trauma group (n=7: Underwent craniotomy followed by brain injury). RESULTS: There were no significant differences groups creatinine levels within 0 and 24 h (0.35 +/- 0.02 and 0.33 +/- 0.03, respectively, p>0.05). Plasma NGAL and KIM1 concentrations were statistically significant different in both control and trauma groups (Friedman p<0.05) and significant differences at both NGAL and KIM-1 concentrations at dual comparisons by means of all sampling time (0-2 h, 0-24 h, and 2-24 h) (Wilcoxon p<0.001, after Bonferroni correction). CONCLUSION: The presence of AKI in patients with mild-to-moderate brain trauma increases the risk of mortality. Early diagnosis of AKI reduces the hospitalization period and requiring of dialysis. Diagnosis of AKI within 24 h with early biomarkers and starting therapy is crucial issues.
20 October 2016 in Turkish Journal of Biochemistry
Objective: To determine the association of missense substitution of alanine 49 threonine (A49T) and valine 89 leucine (V89L) in the steroid-5-alpha-reductase type II (SRD5A2) gene with prostate cancer in Turkish patients. Methods: Eighty patients with prostate cancer and 76 healthy control subjects were evaluated for A49T and V89L polymorphisms in the SRD5A2 gene mutations via real time fluorescence PCR and melting curve analysis. Results: Patients and controls were similar in terms of allele frequencies for polymorphic markers A49T and V89L in the SRD5A2 gene. Most patients had T2b (51.3%), N0 (96.3%) stage tumors with Gleason Score of ≥6 (82.7%) and surgical margin in 28.8%. While 81.3% had no seminal vesicle invasion, 36.3% had capsular invasion. Carrying the 49T allele was associated with higher likelihood of positive surgical margin status (27.5% in 49A vs. 75.0% in 49T, p=0.038) and Gleason Scores of ≥7 (47.5% in 49A vs. 100.0% in 49T, p=0.032) than 49A allele. Conclusion: Our findings revealed no significant difference between patient and control groups in terms of allele frequencies of polymorphic markers in the SRD5A2 gene. T allele was only shown in the patient group. Carrying the 49T allele was associated with higher tumor aggressiveness in A49T polymorphism.
Fibroblast growth factor 21 (FGF21), a pleiotropic hormone, is a significant modulator of energy homeostasis. We evaluated serum FGF21 levels in patients with a deficiency of mitochondrial aminoacyl-tRNA synthetase (mt-aARSs). Six patients with mitochondrial aminoacyl tRNA synthetase deficiency and twelve healthy volunteers were included in this study. Whole-exome sequencing was used for molecular diagnosis. Serum FGF21 levels in the case group and healthy volunteers were analyzed using the enzyme-linked immunosorbent assay. Exome sequencing test revealed nine different pathogenic variants in the AARS2, EARS2, DARS2, SARS2, and WARS2 genes. A statistically significant difference was found between the serum FGF21 levels of the case and control groups: case group (n = 6), 882.49 ± 923.60 pg/mL; control group (n = 12), 20.89 ± 2.63 pg/mL (p < 0.001). The area under the ROC curve for FGF21 in the differential diagnosis of mitochondrial aminoacyl-tRNA synthetase deficiency was 1.000 (0.813–1.000). Sensitivity and specificity were 100%, and positive and negative predictive values were also 100% for an FGF21 cut-off value > 27.4 pg/mL. Assessment of FGF 21 levels as an indicator of mitochondrial damage in mt-aARSs deficiency may provide insight into the level of damage. Investigation of the biochemical mechanisms underlying the different levels of damage caused by different aminoacyl tRNA synthetases will be important in terms of elucidating clinical heterogeneity.
Fibroblast growth factor 21 (FGF21), a pleiotropic hormone, is a significant modulator of energy homeostasis. We evaluated serum FGF21 levels in patients with a deficiency of mitochondrial aminoacyl t-RNA synthetase (aARSs). Six patients with mitochondrial aminoacyl tRNA synthetase deficiency and twelve healthy volunteers were included in this study. Whole-exome sequencing was used for molecular diagnosis. Serum FGF21 levels in the case group and healthy volunteers were analyzed using the enzyme-linked immunosorbent assay. Exome sequencing test revealed nine different pathogenic variants in the AARS2, EARS2, DARS2, SARS2, and WARS2 genes. A statistically significant difference was found between the serum FGF21 levels of the case and control groups: case group (n = 6), 882.49 ± 923.60 pg/mL; control group (n = 12), 20.89 ± 2.63 pg/mL (p < 0.001). The area under the ROC Curve for FGF21 in the differential diagnosis of mitochondrial aminoacyl-tRNA Synthetase Deficiency was 0.933 (0.786-0.962). Sensitivity and Specificity 100%, Positive and Negative Predicted Value 100% were found for FGF21 >27.4 pg/mL cut-off value. Assessment of FGF 21 levels as an indicator of mitochondrial damage in mt-aARS deficiency may provide insight into the level of damage. Investigating the biochemical mechanisms underlying the varying levels of damage caused by different aminoacyl tRNA synthetases is crucial for elucidating clinical heterogeneity.
1 January 2017 in International Journal of Medical Biochemistry
Background/Objectives: In hemoglobinopathies such as β-thalassemia and sickle cell disease (SCD), mitochondrial dysfunction has been implicated in chronic oxidative stress and tissue damage. Circulating cell-free mitochondrial DNA (cf-mtDNA) may reflect mitochondrial injury and serve as a biomarker of disease severity and progression. Methods: This cross-sectional study included four groups: three patient groups—β-thalassemia (n = 36), SCD (n = 11), and genetically confirmed mitochondrial disease (positive control, n = 13)—and one healthy control group (n = 14). Venous blood was collected in EDTA tubes, and plasma was separated by sequential centrifugation. cf-mtDNA was extracted from 200 µL plasma using the Quick-cfDNA™ Serum & Plasma Kit (Zymo Research, Irvine, CA, USA). cf-mtDNA was assessed by qPCR targeting ND1 and COI and analyzed by relative quantification using the 2−ΔΔCt method (Q3 Real-Time PCR System, LongGene). Each sample was run in triplicate. Results: cf-mtDNA levels were significantly higher in the β-thalassemia, SCD, and mitochondrial disease groups compared to healthy controls (p < 0.001). No significant correlations were observed between cf-mtDNA levels and hemoglobin or oxygenation parameters. Conclusions: Elevated relative cf-mtDNA abundance in hemoglobinopathy patients suggests mitochondrial damage, possibly associated with chronic hypoxia and oxidative stress. cf-mtDNA may represent a promising noninvasive biomarker, warranting further longitudinal investigation to evaluate its potential clinical utility.